Adaptation of the Mini-Mental State Examination (MMSE) for the Reunion Island Population

NCT07251647 | Not Yet Recruiting

• 1 other identifier: 2025/CHU/10
• Study Type: interventional
• Target: 400
• Locations: 1 country
• Sites: 7

Brief Summary

The Mini-Mental State Examination (MMSE) is the most widely used cognitive screening and monitoring test for neurocognitive disorders in current clinical practice. Its French version was published in 1998 by the GRECO group (MMSE-GRECO). However, some items of this French version are not adapted to local Reunionese particularities. The main objective is to propose and validate the psychometric properties of an adapted version of the MMSE, to the Reunionese culture (MMSE-RUN) in a healthy population and in a sick population (Alzheimer's Disease and Vascular Cognitive Disorder), and to compare its performance with the MMSE-GRECO.

Conditions

Alzheimer s Disease; Vascular Cognitive Impairment

Keywords

Neurocognitive disorder; cognitive test; screening; Reunion Island

Outcome Measures

Primary Outcomes (3)

• Internal consistency - Cronbach's alpha

  Internal consistency measures the extent to which the items in the test measure the same dimension or concept, in this case overall cognitive efficiency. Internal consistency is commonly measured by Cronbach's alpha, which ranges from 0 (low) to 1 (high). A high coefficient indicates that the test items are similar in content, i.e. homogeneous. A Cronbach's alpha greater than 0.7 is acceptable.

  Day 1

• Construct validity - Exploratory Factor Analysis

  Construct validity allows us to visualise the construction of the test and the concept measured by the instrument in healthy population. The existence of seven independent factors must be demonstrated by Exploratory Factor Analysis: temporal orientation, spatial orientation, learning three words, mental arithmetic, recall, language and constructive praxis.

  Day 1

• Criterion validity - t test

  Criterion validity consists of verifying an instrument's ability to distinguish between individuals; ie, it is the test's ability to clearly identify a deficit in overall cognitive efficiency in a population affected by a pathology, compared to a cognitively healthy population. The validity of this criterion will be assessed using a Student's t-test comparing the MMSE-RUN scores obtained by the healthy subjects group and the pathological subjects group.

  Day 1

Study Arms (2)

Control Arm (Healthy indivuduals)

OTHER

MMSE-RUN and MMSE GRECO questionnaires

Diagnostic Test: MMSE-RUN and MMSE GRECO

Case Arm (Patients with Alzheimer's disease or vascular cognitive impairment)

OTHER

MMSE-RUN and MMSE GRECO questionnaires

Diagnostic Test: MMSE-RUN and MMSE GRECO

Interventions

MMSE-RUN and MMSE GRECO DIAGNOSTIC_TEST

Each participant (control and Case) will complete MMSE-RUN and MMSE-GRECO.

Case Arm (Patients with Alzheimer's disease or vascular cognitive impairment); Control Arm (Healthy indivuduals)

Eligibility Criteria

• Age: 60 Years - 89 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• For the healthy population : aged 60 to 89 years, residing in Reunion for more than 5 years, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.
• For the sick population : aged 60 to 89 years, residing in Reunion for more than 5 years, presenting probable or possible Alzheimer's disease and/or probable vascular cognitive disorder, able to understand the test instructions, available for a one-hour interview, affiliated with a social security scheme, with informed consent.

You may not qualify if:

• For the healthy populationhistory of neurological pathology, neurodegenerative pathology with cognitive expression, refusing to participate in the study, under legal protection.
• For the sick population: acute unresolved medical decompensation or acute psychic decompensation, refusing to participate in the study, under legal protection.

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Réunion: lead

Study Sites (7)

CHU de La Réunion - site Nord - Geriatric department

Saint-Denis, Reunion

Location

CHU de La Réunion - site Nord - Neurology department

Saint-Denis, Reunion

Location

Centre Hospitalier Ouest Réunion (CHOR)

Saint-Paul, Reunion

Location

CHU de La Réunion - site Sud - Geriatric department

Saint-Pierre, Reunion

Location

CHU de La Réunion - site Sud - Neurology department

Saint-Pierre, Reunion

Location

CHU de La Réunion

Saint-Pierre, Reunion

Location

Functional Rehabilitation Center

Sainte-Clotilde, Reunion

Location

MeSH Terms

Conditions

Neurocognitive Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 2, 2025
• First Posted: November 26, 2025
• Study Start: April 1, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: March 12, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

RE (7)